Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17511854 | 0.74 | NQO2 (0.41) | MAPTALDH1A1GLAHPGDACHE | |
| SCHEMBL451100 | 0.68 | — | — | |
| SCHEMBL449767 | 0.68 | — | — | |
| SCHEMBL82645 | 0.68 | — | — | |
| SCHEMBL286948 | 0.67 | ALDH1A1 (0.37) | MAPTALDH1A1HPGD | |
| SCHEMBL286319 | 0.67 | NUDT1 (0.33) | — | |
| SCHEMBL17511981 | 0.63 | HSD17B10 (0.39) | MAPTALDH1A1 | |
| SCHEMBL8727 | 0.62 | ALDH1A1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL69131 | 0.62 | MAPT (0.33) | MAPT | |
| SCHEMBL450208 | 0.62 | GPR3 (0.35) | GPR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | claimed |
| US-10550203-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2020-02-04 | — | — | US | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-20180319905-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-11-08 | — | — | US | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| US-20170015760-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2017-01-19 | — | — | US | claimed |
| US-9469741-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | claimed |
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| WO-1990012010-A1 | SUBSTITUTED CHROMANS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES | PFIZER INC. (US) | 1990-10-18 | — | — | WO | claimed |
| EP-0391625-A1 | Substituted chromans in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1990-10-10 | — | — | EP | claimed |
| EP-0391624-A1 | Substituted 1-[3-heteroarylmethoxy)phenyl] alkanols and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1990-10-10 | — | — | EP | claimed |
| WO-1989003681-A1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA | PFIZER INC. (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0313296-A2 | Substituted chromans and related compounds in the treatment of asthma | PFIZER INC. (US) | 1989-04-26 | — | — | EP | claimed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | claimed |
| EP-0219451-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1987-04-22 | — | — | EP | claimed |
| EP-0118528-A4 | 5-(BICYCLIC NITROGEN-HETEROARYL)PYRID-2-ONES AND THEIR USE FOR INCREASING CARDIAC CONTRACTILITY. | RORER INTERNAT OVERSEAS INC (US) | 1985-09-09 | — | — | EP | claimed |
| EP-0118528-A1 | 5-(BICYCLIC NITROGEN-HETEROARYL)PYRID-2-ONES AND THEIR USE FOR INCREASING CARDIAC CONTRACTILITY | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1984-09-19 | — | — | EP | claimed |
| WO-1984000756-A1 | 5 (BICYCLIC NITROGEN-HETEROARYL)PYRID-2-ONES AND THEIR USE FOR INCREASING CARDIAC CONTRACTILLITY | RORER INT OVERSEAS (US) | 1984-03-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | GPR3 3242/4885MAPT 717/4885ALDH1A1 4836/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | GPR3 415/4885MAPT 539/4885ALDH1A1 953/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | GPR3 3153/4885MAPT 2314/4885ALDH1A1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.